Status:
COMPLETED
Atorvastatin Versus Ezetimibe and Fenofibrate as a Lipid-lowering Strategy
Lead Sponsor:
Queen's University
Conditions:
Dyslipidemia
Vascular Disease
Eligibility:
All Genders
18-85 years
Brief Summary
The primary aim of this study is to evaluate the efficacy and non-inferiority of a lipid-lowering medication regimen comprised of the medications ezetimibe and fenofibrate taken daily, versus atorvast...
Detailed Description
It has been demonstrated in several previous primary and secondary studies that lowering low-density lipoprotein cholesterol (LDL-C) with the use of medications such as 3-hydroxy-3-methylglutaryl-coen...
Eligibility Criteria
Inclusion
- Study is confined to subjects with elevated LDL-C levels 3.0 mmol/L and greater.
Exclusion
- Abnormal liver enzymes (ie, AST, ALT greater than three times the upper limit of normal);
- Creatine kinase levels more than two times the upper limit of normal;
- Uncontrolled ethanol use (this may affect compliance);
- Pregnant or breastfeeding women or women not using adequate contraceptive methods;
- Previous history of intolerance or adverse effects with statins;
- Previous history of intolerance or adverse effects with fibric acid derivatives;
- Previous history of intolerance or adverse effects with ezetimibe;
- Uncontrolled diabetes (HbA1c \> 10%);
- Recent myocardial infarction (within 6 weeks);
- Concurrent enrollment in another study.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00299884
Start Date
January 1 2005
End Date
July 1 2006
Last Update
March 29 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vascular Disease Prevention and Research Centre, Hotel Dieu Hospital
Kingston, Ontario, Canada, K7L 5G2